Abstract
This is the first study to systematically report survival outcomes for pazopanib (PAZ) as a first-line treatment in patients with metastatic epithelioid hemangioendothelioma (EHE). PAZ is active and safe in patients with metastatic EHE and may be considered as an alternative to sirolimus for specific patient subgroups. RECIST criteria should be questioned for evaluation of treatment response in EHE.
Introduction
Epithelioid hemangioendothelioma (EHE) is an exceptionally rare vascular sarcoma with an unpredictable clinical course, affecting fewer than one in a million individuals. Due to its rarity, a globally established standard of care for systemic treatment remains elusive. While the mTOR inhibitor sirolimus is often used as a first-line option, EHE frequently demonstrates resistance to traditional chemotherapy. Multi-targeted tyrosine kinase inhibitors (TKIs) like pazopanib, which target the vascular endothelial growth factor receptor (VEGFR), have shown efficacy in other sarcomas. This study evaluates the clinical outcomes and toxicity of pazopanib as a first-line therapy for metastatic EHE.
Methods and Patient Cohort
A retrospective, single-center analysis was conducted at the University Hospital, LMU Munich, involving 13 patients with histologically confirmed metastatic EHE treated between 2012 and 2023. The median age of the cohort was 43 years. Molecular profiling confirmed the characteristic WWTR1::CAMTA1 gene fusion in 77% of patients.
Pazopanib was administered at a target daily dose of 800 mg. Patients underwent monitoring every three months via CT, MRI, or FDG-PET-CT scans. Primary endpoints included Progression-Free Survival (PFS) and Overall Survival (OS), with response assessed using RECIST v1.1 criteria alongside "clinical benefit" (stable disease and symptom reduction).
Key Results and Clinical Insights
The study revealed a significant discrepancy between traditional tumor shrinkage and clinical outcomes. While no patients achieved a partial or complete response by RECIST criteria, the Clinical Benefit Rate was 62%. This suggests that disease stabilization is a primary therapeutic goal in EHE, and RECIST may underestimate the drug's efficacy.
Survival Outcomes
- Median Progression-Free Survival (PFS): 35.1 months.
- Median Overall Survival (OS): 53.8 months.
- 5-Year OS Rate: 48%.
Patients with serosal effusions or systemic symptoms at baseline had significantly poorer outcomes (median PFS of 6.1 months vs. 62.1 months for those without), identifying a high-risk subgroup.
Safety and Toxicity
Pazopanib demonstrated a manageable safety profile. The most frequent adverse events included hypothyroidism, fatigue, and hair color changes.
Most toxicities were low-grade (CTCAE Grade 1–2) and were successfully managed through dose adjustments rather than permanent discontinuation.
Discussion and Future Directions
This analysis highlights pazopanib as a potent stabilizer for metastatic EHE. The findings underscore the need to redefine success in EHE clinical trials, moving away from RECIST-based shrinkage toward time-to-progression and symptom-based benefits. Future research should focus on identifying predictive biomarkers to better tailor treatment between pazopanib, sirolimus, and emerging therapies, as well as exploring combination strategies to improve tumor reduction.
Summary updated